The 2019 winners are:
Best ADC Platform Technology
Zymeworks (ZymeLink) – Winner
LegoChem Bio (Scaffold Based Approach) – Runner Up
Best New Drug Developer
ADC Therapeutics – Winner
Zymeworks – Runner Up
Most Promising Clinical Candidate
Trastuzumab Deruxtecan (DS-8201a) – Winner
Enfortumab Vedotin (Seattle Genetics/Astellas) – Runner Up
Best Contract Manufacturing (CMO) Provider
BSP Pharmaceuticals – Winner
Millipore Sigma – Runner Up
Best Contract Research (CRO) Provider
PPD – Winner
Abzena – Runner Up
Best Poster Award
Rahul Palchaudhuri from Magenta Therapeutics with his poster on the half-life of their Amanitin Antibody Drug Conjugates.
Richard Bethell at BiVictrix with their paper on Bispecific Antibody Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
Best Pre-Clinical Publication
Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice. Rossin R, Versteegen RM, Wu J, Khasanov A, Wessels HJ, Steenbergen EJ, Ten Hoeve W, Janssen HM, van Onzen AHAM, Hudson PJ, Robillard MS. Nat Commun. 2018 May 4;9(1):1484.
Chemically Defined Antibody- and Small Molecule-Drug Conjugates for in Vivo Tumor Targeting Applications: A Comparative Analysis. Cazzamalli S, Dal Corso A, Widmayer F, Neri D. J Am Chem Soc. 2018 Feb 7;140(5):1617-1621.
Best Clinical Publication
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984.
Individual Input to the Field 2018
Dario Neri (ETH Zurich)
Long Standing Contribution to the Field
Alain Beck (Pierre Fabre)